×
AllNewsImages Maps Videos Books
Search tools

Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets

PR Newswire
Pulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for Assets. Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq:...
4 months ago

Pulmatrix Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation Assets

Morningstar
PR Newswire. FRAMINGHAM, Mass., Aug, 6, 2025. Proposed merger anticipated to close in 2025. As part of the proposed merger, Pulmatrix...
2 weeks ago

How do insiders feel about Pulmatrix Inc. - 2025 Technical Overview & Daily Volume Surge Signals

더경남뉴스
How do insiders feel about Pulmatrix Inc. ✌️【Risk Management】✌️Invest $100 and enjoy the benefits of high returns each month!
3 days ago

Pulmatrix set for merger with Cullgen, seeks asset divestment

Investing.com
Pulmatrix prepares for its anticipated merger with Cullgen Inc., a clinical-stage biopharmaceutical company.
3 months ago

Pulmatrix to Divest 146-Patent Inhalation Technology Portfolio as Cullgen Merger Advances

Stock Titan
Pulmatrix seeks buyers for iSPERSE™ inhalation technology with 146 patents amid strategic merger with Cullgen. Q2 results and merger...
2 weeks ago

Pulmatrix Inc. May Stage Comeback if Support HoldsAnalysts Use RSI to Predict NTES’s Next Move - 2025 EndofYear Setup & Weekly Top Stock Performers List

뉴스영
【Real-Time Stock Group】✌️Boost your savings with a $100 investment. High returns are just a click away!
20 hours ago

Pulmatrix Q2 2025: Proposed merger to close in 2025, divesting iSPERSE technology.

AInvest
... • Pulmatrix to divest assets including iSPERSE™ technology • Proposed merger with Cullgen expected to close in 2025 • Pulmatrix to focus...
2 weeks ago

Pulmatrix, Inc. SEC 10-Q Report

TradingView
Pulmatrix, Inc., a biopharmaceutical company specializing in the development of novel inhaled therapeutic products using its patented...
2 weeks ago

Pulmatrix (PULM) Q2 Revenue Falls 100%

The Globe and Mail
Detailed price information for Pulmatrix Inc (PULM-Q) from The Globe and Mail including charting and trades.
2 weeks ago

Pulmatrix (PULM) Q2 Revenue Falls 100%

AOL.com
GAAP revenue dropped to zero in Q2 2025, with no new product sales or clinical trial sponsorships. Net loss per share (GAAP) was $(0.42) in...
2 weeks ago